Literature DB >> 25185857

Acromegaly--a novel view of the patient. Polish proposals for diagnostic and therapeutic procedures in the light of recent reports.

Marek Bolanowski1, Marek Ruchała, Wojciech Zgliczyński, Beata Kos-Kudła, Agata Bałdys-Waligórska, Grzegorz Zieliński, Tomasz Bednarczuk, Alicja Hubalewska-Dydejczyk, Grzegorz Kamiński, Bogdan Marek, Jacek Daroszewski, Ryszard Waśko, Andrzej Lewiński.   

Abstract

is usually delayed and is often associated with the development of various complications causing premature mortality. In patients with hypertension, heart failure, diabetes, and arthropathy that is non-specific for age, attention should be paid to the occurrence of somatic signs of acromegaly. As a screening test, insulin-like growth factor-1 (IGF-1) concentration should be assessed. Further diagnostic and treatment procedures are possible in specialised centres. The first-line therapy is selective transsphenoidal adenomectomy. Patients with a good prognosis related to a surgical removal of the pituitary tumour should be referred only to centres experienced in performing this type of procedure, after pharmacological preparation. Other patients, and those who have not recovered after surgical treatment, should be subjected to long-term pharmacotherapy with long-acting somatostatin analogues. In each case, the complications of acromegaly should be followed-up long-term and actively treated. This proposed new recommendation should be helpful for the management of patients with acromegaly.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25185857     DOI: 10.5603/EP.2014.0045

Source DB:  PubMed          Journal:  Endokrynol Pol        ISSN: 0423-104X            Impact factor:   1.582


  3 in total

1.  Association between FTO gene polymorphisms and HDL cholesterol concentration may cause higher risk of cardiovascular disease in patients with acromegaly.

Authors:  Aleksandra Franczak; Katarzyna Kolačkov; Aleksandra Jawiarczyk-Przybyłowska; Marek Bolanowski
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

2.  Risk of malignant neoplasms in acromegaly: a case-control study.

Authors:  K Wolinski; A Stangierski; K Dyrda; K Nowicka; M Pelka; A Iqbal; A Car; M Lazizi; N Bednarek; A Czarnywojtek; E Gurgul; M Ruchala
Journal:  J Endocrinol Invest       Date:  2016-10-21       Impact factor: 4.256

3.  Association of Vitamin D Receptor Polymorphisms With Activity of Acromegaly, Vitamin D Status and Risk of Osteoporotic Fractures in Acromegaly Patients.

Authors:  Aleksandra Jawiarczyk-Przybyłowska; Jowita Halupczok-Żyła; Katarzyna Kolačkov; Łukasz Gojny; Agnieszka Zembska; Marek Bolanowski
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-24       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.